Recruitment of Patients in a Phase III Systemic Lupus Erythematosus Study
During the planning of a Phase III Systemic Lupus Erythematosus (SLE) anti-B cell therapy, the Sponsor company called on Pharm-Olam to assist in the identification and enrollment of patients.
The purpose of the study was to determine the viability of a biological agent in treating SLE patients whose disease state was severe, aggressively advancing and poorly controlled. SLE is a notoriously difficult-to-diagnose autoimmune disorder with no known cure.
- Phase III
- Indication: Systemic Lupus Erythematosus (SLE)
- Sites: 32
- Countries: Belarus, Georgia, Guatemala, Mexico, Russia, and Sri Lanka
To see the full case study, click on the image to the right.